Fractional CO2 Laser Therapy System (Z121)
Sanhe PERFECTLASER Technology Co., Ltd. · Decision date Oct 26, 2026
What did the FDA decide?
On October 26, 2026, FDA recorded a substantially equivalent (SE) 510(k) decision for K262627, the Fractional CO2 Laser Therapy System (Z121), submitted by Sanhe PERFECTLASER Technology Co., Ltd. through correspondent Beijing Believe-Med Technology Service Co., Ltd. The device is a Class II laser surgical instrument under 21 CFR 878.4810, product code GEX, reviewed by the General and Plastic Surgery panel. SE clearance is not premarket approval.
The 510(k) summary identifies K241670 (Beijing ADSS Development Co., Ltd.) as predicate and K162169 (Jeisys Medical Inc.) as a reference device, and lists a 10.6 μm wavelength with maximum output power of 35 W, matching the predicate. The stated indications cover body soft tissue ablation, vaporization, excision and coagulation in dermatology, plastic surgery and general surgery, with fractional functionality limited to skin resurfacing. The record does not include clinical performance data, so comparative safety or effectiveness beyond the summary comparison remains unknown.
The summary describes user-set treatment parameters such as laser energy density but gives no specific settings, and the source does not state whether any components or features changed relative to the predicate.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- General, Plastic Surgery
- Decision date
- Oct 26, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K262627
- Regulatory pathway
- 510(k) premarket notification
- Product code
- GEX
- Decision code
- SESE
- Decision date
- Oct 26, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Powered Laser Surgical Instrument.
- Product code
- GEX
- FDA device class
- 2
FDA decision timeline
K262627 received
Application receipt date recorded by FDA.
K262627 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code GEX
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Single Use Optical FiberK262886 | Quanta System Spa | 510(k) clearance | Nov 5, 2026 | FDA |
| Borze, Inc. | 510(k) clearance | Oct 30, 2026 | FDA | |
| Risu Medical Technology Co., Ltd. | 510(k) clearance | Oct 27, 2026 | FDA | |
| Beijing Sea Heart International Science and Technologyco.Ltd | 510(k) clearance | Oct 22, 2026 | FDA | |
| Sanhe PERFECTLASER Technology Co., Ltd. | 510(k) clearance | Oct 20, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Sanhe PERFECTLASER Technology Co., Ltd.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Langfang
Sources and methodology
- Original FDA record: K262627
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

